A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Japanese Women With Postmenopausal Osteoporosis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Japanese Women With Postmenopausal Osteoporosis

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs Romosozumab (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 14 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 29 Jan 2015 Planned End Date changed from 1 Jan 2015 to 1 Mar 2015 according to ClinicalTrials.gov record.
    • 01 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top